Literature DB >> 12478229

Pathophysiology of coronary artery restenosis.

Robert S Schwartz1, Timothy D Henry.   

Abstract

All forms of percutaneous coronary intervention confer injury on the vessel. The arterial response to that injury is the basis for long-term outcome. The stent prevents remodeling but enhances neointimal formation, and it is this neointima that is principally responsible for in-stent restenosis. Neointima forms in response to thrombus, inflammation, intimal and medial dissections, and elastic recoil of the arterial wall when a stent is not placed. Current efforts to solve restenosis center on limiting neointimal hyperplasia through drug-eluting stents and vascular brachytherapy. This article reviews arterial injury during revascularization in both patients and animal models and discusses the nature and formation of neointimal hyperplasia.

Entities:  

Mesh:

Year:  2002        PMID: 12478229

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  28 in total

1.  Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.

Authors:  Andrew D Levin; Neda Vukmirovic; Chao-Wei Hwang; Elazer R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

2.  Treatment of vertebral artery origin stenosis with a Pharos stent device: a single center experience.

Authors:  E Broussalis; A B Kunz; G Luthringshausen; S Klein; M R McCoy; E Trinka; M Killer-Oberpfalzer
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

3.  Enhanced neointimal fibroblast, myofibroblast content and altered extracellular matrix composition: Implications in the progression of human peripheral artery restenosis.

Authors:  Prakash Krishnan; K-Raman Purushothaman; Meerarani Purushothaman; Irene C Turnbull; Arthur Tarricone; Miguel Vasquez; Sachin Jain; Usman Baber; Rheoneil A Lascano; Annapoorna S Kini; Samin K Sharma; Pedro R Moreno
Journal:  Atherosclerosis       Date:  2016-06-30       Impact factor: 5.162

4.  Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.

Authors:  Giuliano Tocci; Emanuele Barbato; Roberta Coluccia; Anna Modestino; Beniamino Pagliaro; Vittoria Mastromarino; Francesca Giovannelli; Andrea Berni; Massimo Volpe
Journal:  Am J Hypertens       Date:  2015-08-13       Impact factor: 2.689

Review 5.  In stent restenosis: bane of the stent era.

Authors:  A K Mitra; D K Agrawal
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

6.  Interstitial flow promotes vascular fibroblast, myofibroblast, and smooth muscle cell motility in 3-D collagen I via upregulation of MMP-1.

Authors:  Zhong-Dong Shi; Xin-Ying Ji; Henry Qazi; John M Tarbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-22       Impact factor: 4.733

7.  Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase.

Authors:  Zachary W Q Moore; David Y Hui
Journal:  J Lipid Res       Date:  2005-08-01       Impact factor: 5.922

8.  Sonic Hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A.

Authors:  David Morrow; John P Cullen; Weimin Liu; Shaunta Guha; Catherine Sweeney; Yvonne A Birney; Nora Collins; Dermot Walls; Eileen M Redmond; Paul A Cahill
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-04-30       Impact factor: 8.311

9.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

10.  Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.

Authors:  Silke Kullmann; Priska Binner; Kirsten Rackebrandt; Andreas Huge; Georg Haltern; Mark Lankisch; Reiner Füth; Eberhard von Hodenberg; Hans-Peter Bestehorn; Thomas Scheffold
Journal:  BMC Cardiovasc Disord       Date:  2009-10-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.